World Health Organization (WHO) member countries adopted a new treaty on May 20, 2025, to improve international coordination ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

The Conversation asked Nicole Hassoun, a professor at Binghamton University and executive director of Global Health Impact, ...

Global health leaders called for the Pandemic Agreement adopted at the 78th World Health Assembly to deliver where past efforts failed—equitable access to life-saving technologies and services during ...

Two global health groups that fund billions of dollars worth of critical medical aid - from childhood vaccines to malaria ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

Dixon Technologies' outperform rating is sustained by BNP Paribas India, citing remarkable FY25 results and future ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...